IL266282B2 - Non-human animals with a transgenic immunoglobulin light chain locus - Google Patents

Non-human animals with a transgenic immunoglobulin light chain locus

Info

Publication number
IL266282B2
IL266282B2 IL266282A IL26628219A IL266282B2 IL 266282 B2 IL266282 B2 IL 266282B2 IL 266282 A IL266282 A IL 266282A IL 26628219 A IL26628219 A IL 26628219A IL 266282 B2 IL266282 B2 IL 266282B2
Authority
IL
Israel
Prior art keywords
human
rodent
gene segments
light chain
gene
Prior art date
Application number
IL266282A
Other languages
English (en)
Hebrew (he)
Other versions
IL266282A (en
IL266282B1 (en
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of IL266282A publication Critical patent/IL266282A/en
Publication of IL266282B1 publication Critical patent/IL266282B1/en
Publication of IL266282B2 publication Critical patent/IL266282B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Environmental Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL266282A 2016-11-04 2017-11-03 Non-human animals with a transgenic immunoglobulin light chain locus IL266282B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662417845P 2016-11-04 2016-11-04
US201762567932P 2017-10-04 2017-10-04
PCT/US2017/060006 WO2018128691A1 (en) 2016-11-04 2017-11-03 Non-human animals having an engineered immunoglobulin lambda light chain locus

Publications (3)

Publication Number Publication Date
IL266282A IL266282A (en) 2019-06-30
IL266282B1 IL266282B1 (en) 2023-12-01
IL266282B2 true IL266282B2 (en) 2024-04-01

Family

ID=62025924

Family Applications (2)

Application Number Title Priority Date Filing Date
IL266282A IL266282B2 (en) 2016-11-04 2017-11-03 Non-human animals with a transgenic immunoglobulin light chain locus
IL308197A IL308197A (en) 2016-11-04 2017-11-03 Non-human animals having an engineered immunoglobulin lambda light chain locus

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL308197A IL308197A (en) 2016-11-04 2017-11-03 Non-human animals having an engineered immunoglobulin lambda light chain locus

Country Status (26)

Country Link
US (3) US10820582B2 (enExample)
EP (4) EP4567119A3 (enExample)
JP (5) JP6884860B2 (enExample)
KR (4) KR102492433B1 (enExample)
CN (2) CN114369157A (enExample)
AU (3) AU2017391167B2 (enExample)
BR (1) BR112019008675A2 (enExample)
CA (1) CA3038720A1 (enExample)
CY (2) CY1123491T1 (enExample)
DK (3) DK3766343T3 (enExample)
ES (3) ES2823305T3 (enExample)
FI (1) FI4082334T3 (enExample)
HR (3) HRP20250695T1 (enExample)
HU (3) HUE071595T2 (enExample)
IL (2) IL266282B2 (enExample)
LT (3) LT3407709T (enExample)
MA (2) MA53935A (enExample)
MX (2) MX385857B (enExample)
PL (3) PL3766343T3 (enExample)
PT (3) PT4082334T (enExample)
RS (3) RS63390B1 (enExample)
RU (1) RU2757665C2 (enExample)
SG (2) SG10201913483XA (enExample)
SI (3) SI3766343T1 (enExample)
SM (3) SMT202000558T1 (enExample)
WO (1) WO2018128691A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10662256B2 (en) 2010-07-26 2020-05-26 Trianni, Inc. Transgenic mammals and methods of use thereof
CN103025884B (zh) 2010-07-26 2015-11-25 特里安尼公司 转基因动物和使用方法
RU2664185C2 (ru) * 2012-02-01 2018-08-15 Регенерон Фармасьютикалз, Инк. Гуманизированные грызуны, которые экспрессируют тяжелые цепи, содержащие домены vl
EP3384030A4 (en) 2015-12-03 2019-07-03 Trianni, Inc. IMPROVED IMMUNOGLULINIVITY
EP4567119A3 (en) 2016-11-04 2025-09-24 Regeneron Pharmaceuticals, Inc. Non-human animals having an engineered immunoglobulin lambda light chain locus
EP4534560A3 (en) 2018-03-24 2025-06-11 Regeneron Pharmaceuticals, Inc. Genetically modified non-human animals for generating therapeutic antibodies against peptide-mhc complexes, methods of making and uses thereof
IL277355B2 (en) 2018-03-26 2025-01-01 Regeneron Pharma Humanized rodents for testing therapeutic agents
IL318469A (en) 2018-06-14 2025-03-01 Regeneron Pharma Non-human animals capable of reorganizing transgenic DH-DH, and their uses
BR112021016173A2 (pt) 2019-02-22 2021-11-03 Regeneron Pharma Roedor geneticamente modificado, métodos de produção de um roedor geneticamente modificado e de produção de um anticorpo anti-nav1.7, célula ou tecido isolado de roedor, linhagem celular imortalizada, embrião de roedor, construto de ácido nucleico de direcionamento, e, hibridoma
KR102953869B1 (ko) * 2019-07-01 2026-04-17 조에티스 서비시즈 엘엘씨 유전자이식 포유동물 및 이의 사용 방법
CN115667532A (zh) * 2020-06-02 2023-01-31 百奥赛图(北京)医药科技股份有限公司 具有共有轻链免疫球蛋白基因座的经遗传修饰的非人动物
US20220090060A1 (en) 2020-09-11 2022-03-24 Regeneron Pharmaceuticals, Inc. Identification and production of antigen-specific antibodies
EP4262373A1 (en) 2020-12-16 2023-10-25 Regeneron Pharmaceuticals, Inc. Mice expressing humanized fc alpha receptors
CA3197426A1 (en) 2020-12-23 2022-06-30 Regeneron Pharmaceuticals, Inc. Methods for obtaining antibodies that bind transmembrane proteins and cells that produce the same
MX2023007401A (es) 2020-12-23 2023-07-06 Regeneron Pharma Acidos nucleicos que codifican anticuerpos modificados por anclaje y usos de los mismos.
JP2024543248A (ja) * 2021-11-10 2024-11-20 トリアニ・インコーポレイテッド トランスジェニック哺乳動物およびその使用方法
GB202217978D0 (en) * 2022-11-30 2023-01-11 Petmedix Ltd Rodents expressing a common light chain
WO2026030428A2 (en) 2024-08-01 2026-02-05 Regeneron Pharmaceuticals, Inc. Prostate-specific antigen peptides and uses thereof
US20260123608A1 (en) 2024-08-06 2026-05-07 Regeneron Pharmaceuticals, Inc. Non-human animals having modified immunoglobulin heavy chain constant region locus and uses thereof
WO2026096736A1 (en) 2024-10-31 2026-05-07 Regeneron Pharmaceuticals, Inc. Rodents expressing humanized polymeric immunoglobulin receptor

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011163311A1 (en) * 2010-06-22 2011-12-29 Regeneron Pharmaceuticals, Inc. Mice expressing alight chain with human lambda variable and mouse constant regions
WO2013096142A1 (en) * 2011-12-20 2013-06-27 Regeneron Pharmaceuticals, Inc. Humanized light chain mice
US20140283150A1 (en) * 2013-03-18 2014-09-18 Kymab Limited Animal Models and Therapeutic Molecules

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07503132A (ja) * 1991-12-17 1995-04-06 ジェンファーム　インターナショナル，インコーポレイティド 異種抗体を産生することができるトランスジェニック非ヒト動物
US5670356A (en) 1994-12-12 1997-09-23 Promega Corporation Modified luciferase
US5874304A (en) 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
GB9823930D0 (en) 1998-11-03 1998-12-30 Babraham Inst Murine expression of human ig\ locus
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7105348B2 (en) 2000-10-31 2006-09-12 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
ES2645563T3 (es) 2001-11-30 2017-12-05 Amgen Fremont Inc. Animales transgénicos que portan genes de cadena ligera de Ig humana
MXPA06000562A (es) * 2003-07-15 2006-03-30 Therapeutic Human Polyclonals Loci de inmunoglobulina humanizada.
ATE537190T1 (de) 2006-06-02 2011-12-15 Regeneron Pharma Hochaffine antikörper gegen den humanen il-6- rezeptor
PL2346994T3 (pl) 2008-09-30 2022-04-19 Ablexis, Llc Myszy knock-in do wytwarzania chimerycznych przeciwciał
KR101711222B1 (ko) * 2008-12-18 2017-02-28 에라스무스 유니버시티 메디컬 센터 로테르담 인간화 항체들을 발현하는 비-인간 유전자이식 동물들 및 그의 이용
DK3241435T3 (da) * 2009-07-08 2021-08-23 Kymab Ltd Dyremodeller og terapeutiske molekyler
RU2425880C2 (ru) * 2009-07-30 2011-08-10 Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН Способ получения трансгенных мышей
WO2011115476A1 (en) 2010-03-17 2011-09-22 N.V. Nutricia Infant nutrition for improving fatty acid composition of brain membranes later in life
CN105861548B (zh) 2011-02-25 2020-01-10 瑞泽恩制药公司 Adam6小鼠
EP4074833A1 (en) 2011-10-17 2022-10-19 Regeneron Pharmaceuticals, Inc. Restricted immunoglobulin heavy chain mice
US9253965B2 (en) * 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
RS57582B1 (sr) * 2013-02-20 2018-11-30 Regeneron Pharma Nehumane životinje sa modifikovanim sekvencama imunoglobulinskog teškog lanca
MX2015010841A (es) 2013-02-20 2016-05-09 Regeneron Pharma Modificacion genetica de ratas.
WO2015049517A2 (en) * 2013-10-01 2015-04-09 Kymab Limited Animal models and therapeutic molecules
MX388127B (es) 2013-12-11 2025-03-19 Regeneron Pharma Metodos y composiciones para la modificacion dirigida de un genoma.
DK3152312T3 (da) 2014-06-06 2020-04-06 Regeneron Pharma Fremgangsmåder og sammensætninger til modifikation af et mållocus
US9738897B2 (en) 2014-06-23 2017-08-22 Regeneron Pharmaceuticals, Inc. Nuclease-mediated DNA assembly
EP3221457B1 (en) 2014-11-21 2019-03-20 Regeneron Pharmaceuticals, Inc. Methods and compositions for targeted genetic modification using paired guide rnas
MX388784B (es) 2014-12-19 2025-03-20 Regeneron Pharma Métodos y composiciones para la modificación genética dirigida a través de direccionamiento múltiple de una sola etapa.
EP4567119A3 (en) 2016-11-04 2025-09-24 Regeneron Pharmaceuticals, Inc. Non-human animals having an engineered immunoglobulin lambda light chain locus

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011163311A1 (en) * 2010-06-22 2011-12-29 Regeneron Pharmaceuticals, Inc. Mice expressing alight chain with human lambda variable and mouse constant regions
WO2013096142A1 (en) * 2011-12-20 2013-06-27 Regeneron Pharmaceuticals, Inc. Humanized light chain mice
US20140283150A1 (en) * 2013-03-18 2014-09-18 Kymab Limited Animal Models and Therapeutic Molecules

Also Published As

Publication number Publication date
MX2021010556A (es) 2021-10-01
CY1123491T1 (el) 2022-03-24
MX385857B (es) 2025-03-18
CN114369157A (zh) 2022-04-19
PT4082334T (pt) 2025-05-21
IL266282A (en) 2019-06-30
ES3035365T3 (en) 2025-09-02
KR20190076024A (ko) 2019-07-01
MA44091A (fr) 2018-10-24
FI4082334T3 (fi) 2025-06-10
JP7386292B2 (ja) 2023-11-24
WO2018128691A8 (en) 2019-02-28
SMT202500204T1 (it) 2025-07-22
EP3766343A1 (en) 2021-01-20
CA3038720A1 (en) 2018-07-12
RU2021129958A (ru) 2021-11-02
SI4082334T1 (sl) 2025-06-30
EP4082334B1 (en) 2025-03-26
SMT202000558T1 (it) 2020-11-10
NZ753456A (en) 2021-08-27
MX2019005256A (es) 2019-08-05
HRP20250695T1 (hr) 2025-08-01
PL3766343T3 (pl) 2022-09-26
SI3407709T1 (sl) 2020-10-30
RS66884B1 (sr) 2025-07-31
EP3407709A1 (en) 2018-12-05
RS63390B1 (sr) 2022-08-31
ES2823305T3 (es) 2021-05-06
AU2017391167A1 (en) 2019-05-30
RU2757665C2 (ru) 2021-10-20
SG10201913483XA (en) 2020-03-30
EP3766343B1 (en) 2022-05-11
SI3766343T1 (sl) 2022-06-30
LT3407709T (lt) 2020-10-12
KR102319069B1 (ko) 2021-11-01
CY1125474T1 (el) 2025-05-09
JP2020501516A (ja) 2020-01-23
JP2021090455A (ja) 2021-06-17
BR112019008675A2 (pt) 2019-07-09
HRP20201403T1 (hr) 2020-11-27
DK3766343T3 (da) 2022-06-20
WO2018128691A1 (en) 2018-07-12
CN109996441A (zh) 2019-07-09
KR20210134059A (ko) 2021-11-08
LT3766343T (lt) 2022-06-10
HUE071595T2 (hu) 2025-09-28
AU2017391167B2 (en) 2024-02-15
HUE061980T2 (hu) 2023-09-28
SG11201903344XA (en) 2019-05-30
DK4082334T3 (da) 2025-06-02
EP3407709B1 (en) 2020-07-29
EP3407709B9 (en) 2021-10-06
AU2024200582B2 (en) 2026-04-09
IL266282B1 (en) 2023-12-01
KR102492433B1 (ko) 2023-01-30
JP6884860B2 (ja) 2021-06-09
CN109996441B (zh) 2022-02-08
AU2024200582A1 (en) 2024-03-28
JP2022130725A (ja) 2022-09-06
JP2025166207A (ja) 2025-11-05
LT4082334T (lt) 2025-05-26
MA53935A (fr) 2021-12-22
EP4082334A1 (en) 2022-11-02
HUE052087T2 (hu) 2021-04-28
DK3407709T3 (da) 2020-08-31
US20210029978A1 (en) 2021-02-04
PT3407709T (pt) 2020-08-20
US12433264B2 (en) 2025-10-07
RU2019112589A3 (enExample) 2021-03-30
EP4567119A2 (en) 2025-06-11
PT3766343T (pt) 2022-05-30
JP2023053400A (ja) 2023-04-12
SMT202200259T1 (it) 2022-07-21
AU2026205397A1 (en) 2026-07-30
KR20240055863A (ko) 2024-04-29
US20180125043A1 (en) 2018-05-10
EP4567119A3 (en) 2025-09-24
US10820582B2 (en) 2020-11-03
KR20230020550A (ko) 2023-02-10
PL3407709T3 (pl) 2021-01-11
PL4082334T3 (pl) 2025-08-11
HRP20220888T1 (hr) 2022-10-28
RU2019112589A (ru) 2020-12-04
ES2915609T3 (es) 2022-06-23
US20260068860A1 (en) 2026-03-12
IL308197A (en) 2024-01-01
KR102658529B1 (ko) 2024-04-19
RS60886B1 (sr) 2020-11-30

Similar Documents

Publication Publication Date Title
AU2024200582B2 (en) Non-human animals having an engineered immunoglobulin lambda light chain locus
CA3084049A1 (en) Non-human animals having an engineered immunoglobulin lambda light chain and uses thereof
AU2020289554A1 (en) Non-human animals having a limited lambda light chain repertoire expressed from the kappa locus and uses thereof
IL279311B2 (en) Non-human animals capable of DH–DH rearrangements in immunoglobulin heavy chain coding sequences
HK40127071A (en) Non-human animals having an engineered immunoglobulin lambda light chain locus
HK40082722B (en) Non-human animals having an engineered immunoglobulin lambda light chain locus
HK40082722A (en) Non-human animals having an engineered immunoglobulin lambda light chain locus
HK40045047A (en) Non-human animals having an engineered immunoglobulin lambda light chain locus
HK40045047B (en) Non-human animals having an engineered immunoglobulin lambda light chain locus
HK40001433B (en) Non-human animals having an engineered immunoglobulin lambda light chain locus
HK40001433A (en) Non-human animals having an engineered immunoglobulin lambda light chain locus
NZ753456B2 (en) Non-human animals having an engineered immunoglobulin lambda light chain locus